immuno-oncology agents for mm: checkpoint inhibitors and nk-cells
Published 6 years ago • 1.2K plays • Length 5:20Download video MP4
Download video MP3
Similar videos
-
1:05
the future of immuno-oncology
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:34
checkpoint inhibitors and their potential role in mm
-
3:15
promising results for mm treatment with natural killer cells
-
1:51
checkpoint inhibition in the treatment of mpns
-
4:27
the role of immune checkpoint inhibitors in mds
-
0:59
what is immuno-oncology?
-
3:21
nox2: a potential immune checkpoint for inhibition in aml
-
5:42
immune checkpoint inhibitors in mds and aml
-
18:39
immunotherapy in myeloma: current strategies and future perspectives
-
0:36
the potential of immunotherapies in the myeloma treatment landscape
-
7:32
current immune checkpoint inhibitor trials in aml/mds
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
1:52
single-cell and immune sequencing to predict response and resistance to car-t therapy in r/r mm
-
4:59
checkpoint inhibitors in aml
-
2:18
adoptive t-cell therapy for the treatment of mm
-
6:31
what are checkpoint inhibitors?
-
5:14
nk-cell enhancement: trail variant
-
4:55
checkpoint inhibitor combination approaches for aml/mds: an update